What have we been doing?

Read all the latest news from NeoBiotechnologies.

Inter Viruses Increase, Expert Shares Immune Advice

Immunity expert reveals subtle signs you’re pushing your body too hard

NeoBiotechnologies Expands Access to In-House Validated Antibodies for IVD, CDx, and Pharma Sectors

Molecular Interplay between Dormant Bone Marrow-Resident Cells (BMRCs) and CTCs in Breast Cancer

Efficient wet-spinning of pre-aligned microtissues for 3D bioprinting complex tissue alignment

NeoBiotechnologies Driving Breakthroughs in Medicine with Reliable Antibody Solutions

Hepatocyte TM4SF5-mediated cytosolic NCOA3 stabilization and macropinocytosis support albumin uptake and bioenergetics for hepatocellular carcinoma progression

Z-form DNA-RNA hybrid blocks DNA replication

Blebbisomes are large, organelle-rich extracellular vesicles with cell-like properties

Skewed adaptive immune responses are involved in AATD emphysema

Spatial omics-based machine learning algorithms for the early detection of hepatocellular carcinoma

Human monocyte-derived macrophages shift subcellular metalloprotease activity depending on their activation state

CD103+ cDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases

Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer

Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer

Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma

Tumor-Suppressive Cross-Linking of Anti-T. cruzi Antibodies in Acute Lymphoblastic Leukemia

Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice

What is causing the surge in cancer among young people? Dr. Tandon advocates for the continued investment on treatment research.

Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer

Dr. Atul K. Tandon discusses the differences between targeted cancer therapy and chemotherapy

Practical implications of androgen receptor inhibitors for prostate cancer treatment

POU6F2, a risk factor for glaucoma, myopia and dyslexia, labels specific populations of retinal ganglion cells

NeoBiotechnologies Receives 2023 Best of Union City Award

Dr. Atul Tandon, Founder of NeoBiotechnologies, named one of the Top 10 Global Leaders from AIIMS Alumni – 2023

Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells

CITATION: Clinical-Grade Validation of an Autofluorescence Virtual Staining System With Human Experts and a Deep Learning System for Prostate Cancer

Dr. Atul K. Tandon of NeoBiotechnologies discusses the NLRP3/caspase1/IL-18 signaling pathway in the treatment of eosinophilic esophagitis (EoE)

Leading biotech company launches exclusive license to 10,000 validated antibodies, elevating cancer research efforts worldwide

NeoBiotechnologies Unveils Critical Portfolio of Mouse & Rabbit Monoclonal Antibodies for Cancer Research & Diagnosis

Accumulation of Iron Oxide-Based Contrast Agents in Rabbit Atherosclerotic Plaques in Relation to Plaque Age and Vulnerability Features

NeoBiotechnologies interviewed by BioSpace regarding Lean, Fractional C-Suites

Dr. Atul K. Tandon quoted in Pharmaceutical Press’ article on What Techniques Effectively Educate Doctors About New Medications

Dr. Atul K. Tandon talks to GritDaily about overcoming resistance to technological change

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming

Single-Nucleus Transcriptional Profiling of Chronic Kidney Disease after Cisplatin Nephrotoxicity

Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma

The identification of a TNBC liver metastasis gene signature by sequential CTC‐xenograft modeling

IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors

When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions

A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factors

NeoBiotechnologies And CDI Laboratories Form Alliance To Distribute CDI’s 2500 Monospecific Transcription Factor Antibodies

Ximbio Partnership Helps Expand NeoBiotechnologies’ Hybridoma Collection

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK